Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa's Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants
MARIETTA, Ga., Aug. 12, 2025 /CNW/ -- Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved its Pediatric Investigation Plan (PIP) for its investigational biologic, zelpultide alfa, in its initial indication for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants born between 22 and 27 weeks gestational age.
Zelpultide alfa is a first-in-class recombinant human surfactant protein D (rhSP-D) designed to modulate immune responses to reduce inflammation, enhance pathogen clearance, and support surfactant homeostasis for improved lung function.
"We are pleased to have reached agreement with the PDCO on the Pediatric Investigation Plan and pivotal study design for zelpultide alfa, a ground-breaking therapy being developed to prevent BPD in very preterm infants, a highly vulnerable population with no approved preventative treatments," said Dr. Marc Salzberg, Chairman, Chief Executive & Medical Officer of Airway Therapeutics. "This marks a significant milestone in advancing a potential first-in-class preventive therapy to improve outcomes for these fragile infants and address a critical unmet medical need."
The approved PIP includes the design and execution plan for a pivotal Phase 2b/3 clinical trial. The Phase 2b trial will evaluate two different dose levels of zelpultide alfa administered for up to seven days, compared to placebo. Following completion of treatment in 150 patients (50 per arm), one dose will be selected for continuation into Phase 3, during which approximately 216 additional patients will be enrolled. As part of the study, Airway Therapeutics will assess a three-day consecutive BPD evaluation endpoint, which may contribute to the development of improved outcome measures during the studies.
"Bronchopulmonary dysplasia remains one of the most challenging complications in neonatal intensive care, with long-term consequences for respiratory and neurodevelopmental outcomes," said Dr. Daniele De Luca, Principal Investigator of the trial and Professor of Pediatrics (Neonatology) at Paris Saclay University. "Zelpultide alfa represents a novel and scientifically promising approach, grounded in our understanding of immune modulation and tissue injury. This study will allow us to rigorously evaluate its potential to change clinical practice by addressing the root drivers of lung injury in very preterm infants."
Airway Therapeutics plans to submit the PDCO-approved protocol immediately to health authorities in Italy (AIFA), Spain (AEMPS), and Israel (MoH), with the objective of initiating the clinical trial in these countries in late Q3 or Q4 2025. Additional submissions will follow in France, Germany, Belgium, and Poland, along with planned regulatory filings in Argentina, Australia, and the United States.
About Zelpultide Alfa
Zelpultide alfa is a recombinant human surfactant protein D (rhSP-D) precisely engineered to replicate the native protein's full quaternary structure and biological function, incorporating optimized glycosylation through advanced cell line technology.
Its therapeutic activity is driven by three key mechanisms: modulation of immune responses to mitigate excessive inflammation, enhancement of pathogen recognition and clearance, and maintenance of surfactant homeostasis to support pulmonary function. As a versatile biologic platform, zelpultide alfa is being developed for patients across all age groups—from preventing bronchopulmonary dysplasia (BPD) in very preterm infants to treating acute and chronic respiratory, inflammatory and infectious conditions in adults.
Zelpultide alfa's lead indication, BPD prevention, is currently progressing through a pivotal Phase 2b/3 clinical trial, following Phase 1 study that demonstrated a favorable safety and tolerability profile.
About Airway Therapeutics
Airway Therapeutics is a clinical-stage biopharmaceutical company developing a new class of biologic therapies to redefine the prevention and treatment of respiratory, inflammatory, and infectious diseases. Its lead candidate, zelpultide alfa, is currently in late-stage clinical development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, a condition with no approved preventive therapies. As a platform biologic, zelpultide alfa is also being advanced for broader application across age groups and disease settings, with the goal of improving outcomes for vulnerable patient populations.
For more information, please visit https://www.airwaytherapeutics.com
Company Contact:Libba MuziAirway Therapeuticsmuzi@airwaytherapeutics.com513-770-9630
Media Contact:Tony Russo, Ph.D. Russo Partners, LLCtony.russo@russopartnersllc.com212-845-4251
View original content to download multimedia:https://www.prnewswire.com/news-releases/airway-therapeutics-receives-european-medicines-agency-pediatric-committee-approval-for-zelpultide-alfas-study-plan-in-bronchopulmonary-dysplasia-for-very-preterm-infants-302527004.html
SOURCE Airway Therapeutics
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2025/12/c5101.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
The rich already know how private equity mints money — and it's not from a 401(k)
The ultrawealthy are envied for many reasons. For instance, we wish we could access the same private-market investments that they favor. Now, after the White House issued an executive order on Aug. 7, you may be able to invest like the billionaires do. Homeowners rush to refinance as mortgage-rate plunge opens window of opportunity My wife and I are in our 50s and have $11 million. We're not leaving it to our kids. Is that wrong? You could receive up to $7,500 from the AT&T settlement. Here's how class-action suits work. But would you want to? The executive order allows ordinary retirement savers to invest in private assets and cryptocurrency. This will expand investment options for anyone with a 401(k) or similar tax-advantaged retirement plan. It is a big deal — opening part of America's $12.4 trillion defined-contribution market to private-asset managers. The largest private-equity firms and other asset managers are salivating at the opportunity to pitch this untapped market of retirement savers. Private assets encompass a range of investments that do not trade on a public exchange. Examples include hedge funds, private equity, private credit and infrastructure. The case for private assets is they can provide a buffer against inflation — plus steady returns. The downsides include high fees, illiquidity and complexity. The nation's biggest asset managers welcome the executive order. They want to develop funds that make private assets easier for people to buy, and argue that the added diversification serves savers' best interests. Larry Fink, chief executive of BlackRock BLK, says retirement savers should replace the traditional 60% stocks/40% bonds asset-allocation model with a 50/30/20 split: 50% stocks, 30% bonds and 20% private assets. Read: Larry Fink proposes an alternative to the 60/40 portfolio. It means more fees. Should you be excited about this widening menu of investment choices? It depends on whom you ask. Some investment professionals like the idea of making private assets more available to more people. 'Historically, a number of private-market strategies have produced higher performance and additional diversification in defined-benefit pensions,' says Peter von Lehe, head of investment solutions and strategy at Neuberger Berman. 'It's appropriate that a broader range of investors have access to private assets in their defined-contribution plans because of the potential for return and diversification that these long-term investments can provide.' However, von Lehe cautions that these investments are illiquid and 'have a higher degree of complexity.' He says his 'most appropriate use case' for private-market investments is through professionally managed target-date funds or other funds that allocate a percentage of defined-contribution money to these complex but potentially more lucrative alternatives. Read: Here's something the rich know about managing investment risk that can help you, too Financial advisers have differing views on the role of private assets in client portfolios. Steven Roge, a certified financial planner in Bohemia, N.Y., says private markets are not for everyone. 'It's for people in the wealth-accumulation phase, say 40 to 50 years old, who have a long time horizon and a high risk tolerance,' Roge says. 'And they have to be sophisticated enough to understand it. We know if they don't understand it, they may not stick with it.' Of the firm's 300 clients, he says that 'only about a dozen' fit the bill for adding private-market assets to their retirement accounts. Even with the expanded investment options that may result from the White House's action, Roge remains a fan of passive strategies for most investors. 'Indexing is how they will win over the long run,' he says. 'But some clients want something that's special and different' as they seek market-beating returns. Given the illiquidity of private assets, Roge anticipates setting expectations for those clients who tend to monitor their portfolio daily — and who engage in frequent trading. 'These private investments may only price four times a year,' Roge says. 'That's not enough action for certain clients who track their portfolio like a hawk.' In his personal portfolio, Roge uses private markets — especially private equity — to diversify his holdings. He says he allocates about 25% to alternative assets. 'It helps me sleep at night knowing my portfolio isn't being pushed around by the volatility of public markets,' he says. Roge adds that he is not concerned about the current high valuations of private-equity funds. 'The valuations [of private-equity funds] are more realistic than the erratic valuations we see in public markets on a daily basis,' he says. Other advisers are more skeptical of the White House executive order. 'It's less being done out of interest for the general public and more for private industry lobbying the [Trump] administration,' says Alex Ruda, an adviser in Silver Spring, Md. The executive order undoubtedly pleases asset managers and private-equity firms. For years, they've wanted to attract retirement savers' money. These savers bear primary responsibility for managing their 401(k) compared with today's older retirees, many of whom receive employer-funded defined-benefit pensions. While some younger savers enjoy picking their investments, others dread it. 'The average American worker isn't equipped to navigate these complex [private-market] investments,' Ruda says. 'And they may fall prey to a little performance chasing given where we are in the market cycle' — as private markets have outperformed publicly traded stocks since 2000. Ruda feels so strongly about not incorporating private assets into client portfolios that he's willing to forgo newcomers who express such interest. 'If I wanted to broaden my client base, I'd have to play to what they want,' he says. 'But I don't have to do that. So I'd say to them, 'I'm not the best fit.'' Read next: Here's what it's like to invest in private equity — and why you don't want it in your 401(k) More: As private equity enters retirement plans, is it too dangerous for average investors to jump in? I'm a senior who barely survives on $1,300 a month. No way could I live on $1,000. 'I am a senior citizen': My car needs $3,500 for repairs, but only has a trade-in value of $6,000. Do I bother fixing it?
Yahoo
15 minutes ago
- Yahoo
I'm a 67-year-old runner — these are the 6 best men's running shoes in 2025
Best running shoes for seniors from ASICS, Nike, Saucony and more. After years of playing soccer, squash and distance running on hard surfaces, I needed both my knees scoped (surgery to repair torn cartilage). Initially, my doctor recommended I stop running altogether. But after extensive badgering, he eventually gave me the green light to give running another shot, providing I took careful steps — literally. Steps as in: ramping up slowly (not unlike when I first began running as a late starter at 39), not running too hard or for too long, and importantly: choosing the right shoes. All of which has made it possible for me to keep running today as a 67-year-old. And why not? As studies conclusively show, running helps keep seniors young. Whether you're in your 30s, your 50s, your 60s or beyond, these shoes will help you to put your best foot forward. Best shoes for new runners One of the key differences between walking and running is that with running, you're hitting the ground with twice as much force. Experts estimate the force of walking is 1.5 times your body weight, while running can be 2-3 times. Thus, choosing shoes that provide enough support is a key consideration. Other good reads: Best running shoes for men in 2025, according to a competitive distance runner Best hiking shoes, clothes and accessories for men in 2025, according to an avid hiker Best men's running shoes for racing and marathons in 2025, according to a competitive athlete Best for runners returning from injury After almost 30 years of running, I've experienced pretty much every kind of injury you can think of. So I know first-hand how important it is when you start back up to find a balance between choosing shoes that provide adequate support, but are light and responsive enough to be a "go-to shoe" when you are ready to pick up the pace. Best trail shoes for running and hiking Running or walking on trails, especially hilly ones, is a great way to ramp up your cardio without stressing your body as much as running faster does. They can often provide a softer surface to run on, too. That said, I've been on many trails where you have to navigate stones, rocks and tree roots, so having shoes with good grip and protection should be top of mind.
Yahoo
15 minutes ago
- Yahoo
GM wows with Corvette, Cadillac concepts at Monterey Car Week
CARMEL, Calif – GM brought some Detroit muscle to the rarified air of Monterey Car Week — with a twist. While the Corvette nameplate falls under the Chevrolet brand, more and more it stands out on its own. At The Quail event in Carmel Valley, where multi-million dollar Paganis are displayed alongside priceless gullwing Mercedes SL coupes (and the parking lot is a show in and of itself), Corvette showed off two concepts that showed where the sportscar is headed in the future. The CX and its racing-inspired twin the CX-R, evoke supercar looks that go beyond the current 'C8' Corvette. The two concepts feature fighter jet-style interiors, with a trick canopy opening to boot. The twist — the CX is all electric, which is becoming a rarity at the higher end, and the CX-R features hybrid power. The racy CX-R will also be a drivable car in the Gran Turismo 7 racing game on PlayStation. And the response, beyond the oohs and ahhs, was strong for vehicles that aren't going on sale. 'We've had a number of customers that have already said, 'Could we buy one of those vehicles today?,'' said Rory Harvey, EVP and President of Global Markets, from the Quail Event to Yahoo Finance. Harvey, who essentially leads on all GM brands globally, noted that customers were asking to buy a vehicle with no pricing info, and wouldn't even be released. It was a good opportunity though, to collect future client info from buyers who typically own multiple cars. 'Just listening to the customers, the enthusiasts that are on the stage, I mean, the feedback is outstanding,' Harvey said. The UK-born exec noted that Corvette, in his opinion, was already at supercar levels, with competitive lap times at places like the Nurburgring in Germany, and 38% market share in the luxury sports car segment, making it the leader. Harvey's purview extends to Cadillac, where the luxury brand showed off its 'Elevated Velocity' concept, a cross-over style EV SUV meant to evoke the high-desert landscape. The new design language may hint at more curves and swooping design, as opposed to Cadillac's traditional angular features and vertical light bars. Regardless, Cadillac as a brand has been on a winning streak with its combination of traditional gas powered cars like the Escalade and CT5 sedans, and EVs like the Lyriq and Optiq. 'Cadillac now has done 12 consecutive quarters of year-on-year growth, which is absolutely superb. But in quarter two, Cadillac is now the number one luxury brand for EVs. So again, that's really, really strong,' Harvey said. 'We've launched so many new products over the course of the last two years, and that momentum continues to build. So we're looking at, how do we keep our foot on the accelerator pedal and build even further?' Harvey said he wasn't terribly concerned over the upcoming loss of the EV tax credit, because the brand would be able 'flex' into its other gas-powered offerings like the XT crossovers if its EVs were not price competitive. While a nice game plan, it doesn't address the fact the company invested heavily in EVs, and might take a hit to sales. Another challenge is tariffs, where GM took a big hit in the second quarter and stands to feel more pain in the second half of the year. Harvey noted the trade deals in place are mostly preliminary, so when the details come out the company will have a hard look at its manufacturing footprint, product portfolio in terms of territory, and where the company can minimize its tariff exposure. 'We've publicly stated that we believe that we can mitigate approximately 30% of the impact of tariffs; so, we're in a strong position at the moment,' Harvey said of GM's ability to pivot around President Trump's tariff war. Harvey still believes GM is in a great spot regardless of tariffs, and it's because of products like the current Corvette and Cadillac portfolio — cars that are selling well in the marketplace. 'If you looked at just General Motors sales in the US, we are the fastest growing brand, full stop. And if you look to the nearest competitor, they're about half the level of growth that we've got. So customers love our products.' Pras Subramanian is the lead auto reporter for Yahoo Finance. You can follow him on X and on Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
